Endocyte, Inc. (ECYT) Sets 52-Week High

May 16, 2018 - By Norman Soto

During 2017 Q4 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio is positive. 15 rose stakes while 19 funds took stakes. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Deutsche National Bank Ag holds 615 shs. Millennium Limited Liability Corporation holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 324,026 shs. Adage Cap Gp Lc, Massachusetts-based fund reported 122,000 shs. First Fin Corp In holds 0% or 100 shs in its capital. Parallax Volatility Advisers Limited Partnership owns 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 7,613 shs. Barclays Public invested in 103,109 shs or 0% of the stock. Ra Capital Management Ltd accumulated 3.36 million shs or 1.2% of the stock. 80,856 were accumulated by Northern. Partner Fund Mngmt L P stated it has 3.44M shs. Morgan Stanley, New York-based fund reported 166,663 shs. New York-based Spark Mngmt Limited Liability Corporation has invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Eam Invsts Ltd reported 0.06% stake. 1.63 million were accumulated by Vanguard Inc. Royal National Bank Of Canada holds 0% or 12,882 shs. Perceptive Limited Co has invested 0.21% in Endocyte, Inc. (NASDAQ:ECYT).

Endocyte, Inc. registered $45,677 net activity with 0 buys and 1 sale since March 9, 2018.

Today 1-year high was reached by Endocyte, Inc. (NASDAQ:ECYT) with $13.44 target or 7.00 % above today’s $12.56 price per share. It was announced on May, 16 by Barchart.com. The company has $866.25M MC. $60.64M more could be NASDAQ:ECYT valuation at $13.44 share price.

ECYT is hitting $12.56 during the last trading session, after increased 3.72%.Endocyte, Inc. has volume of 2.13M shares. Since May 16, 2017 ECYT has risen 296.90% and is uptrending. The stock outperformed the S&P 500 by 285.35%.

Earnings report for Endocyte, Inc. (NASDAQ:ECYT) is expected on August, 14., RTT reports. Analysts expect change of 32.14 % or $0.09 from previous year’s $-0.28 earnings per share compared to current’s $-0.19 earnings per share. 18.75 % negative EPS growth is what analysts predict. $-0.16 earnings per share was announced for previous quarter.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

In total 3 analysts cover Endocyte (NASDAQ:ECYT). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ECYT) has 100% bullish analysts. With $20 highest and $17 lowest PT, Endocyte has $18.50 average PT or 47.29% above the current ($12.56) price. 3 are the (NASDAQ:ECYT)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Tuesday, February 27 Cowen & Co upgraded Endocyte, Inc. (NASDAQ:ECYT) to “Outperform” rating.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were published by: Globenewswire.com which released on May 02, 2018 “Endocyte Announces First Quarter 2018 Earnings Call”, also Nasdaq.com on April 26, 2018 published “New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals …”, the next Seekingalpha.com is “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. Globenewswire.com has article titled “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The company has $866.25 million market cap. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Currently it has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.